Increased risk of second malignancy in pancreatic intraductal papillary mucinous tumors: Review of the literature

Table 1 Studies reporting pancreatic cancer and extrapancreatic malignancies incidence in patients with intraductal papillary mucinous tumors

Ref.	Year	Study design	n (IPMN)	Prevalence EPM	Colon Ca	Gastric Ca	NET	Group 23	n(group 2)	Prevalence EPM - group 2 (%)	P vaule
Lubezky et al[19]	2012	Retrospective	82	20%	31%	NR	NR	Pancreatic ductal adenocarcinoma	150	6	0.002
Riall et al[20]	2007	Population-based	992	10%	3%	0.1%	NR	Other neoplasm1	18655	10	NS
Yoon et al[21]	2008	Retrospective	210	33.8%	7%	14%	NR	Non-IPMN cystic pancreatic neoplasm	175	12	< 0.001
Kamisawa et al[22]	2005	Retrospective	79	35%	9%	15%	NR
Ishida et al[23]	2008	Retrospective	61	24.6%	8%	10%	NR
Ishida et al[24]	2013	Case report	1	100%	0	0	100
Goh et al[25]	2006	Case report	3	100%	0	0	100
Eguchi et al[26]	2006	Retrospective	69	42%	12%	6%	NR	Other neoplasm2	301	12	< 0.001
Choi et al[27]	2006	Retrospective	61	39%	7%	13%	NR	Other pancreatic neoplasm	38	8	< 0.001
Calculli et al[28]	2010	Retrospective	142	14.1%			NR
Reid-Lombardo et al[29]	2010	Retrospective	471	52%	4%	0	NR
Oh et al[30]	2009	Retrospective	37	38%	8%	8%	NR
Baumgaertner et al[31]	2008	Case-control	178	17%	10%	NR	NR	Aged and gender-matched control	356	8.4	0.003
Tanno et al[32]	1999	Retrospective	42	48%	12%	10%	NR
Larghi et al[33]	2013	Multicentric cohort	390	23.6%	12.4%	NR	NR
Tewari et al[34]	2013	Case report	3	100%	0	0	100%
Uehara et al[35]	2008	Retrospective	60	54	NR	NR	NR

¹Data from SEER Tumor Registry;

²Data from Osaka Cancer Registry;

³Control-group, if present;

⁴Pancreatic adenocarcinoma. NR: Not reported; IPMN: Intraductal papillary mucinous tumor.